In Los Angeles, a newsworthy event from the autumn of 1966, especially for the medical community, was the opening of the Jules Stein Eye Institute on the campus of the University of California Los Angeles. Far more than the dedication of a building, the event signaled the beginning of an ongoing commitment to the preservation of sight that has impacted millions of patients, medical professionals, and researchers over the last 50 years.
Worried about rupture during a deep anterior lamellar keratoplasty (DALK)? You may be overreacting. While rupture is the most common complication of DALK, its repair is not as difficult as commonly thought.
To evaluate patients with uveitis, a tailored multimodal imaging approach can be very helpful both in the clinic and in clinical trials. With selective imaging, you can integrate and correlate the data from different images for a more conclusive diagnosis.
Tocilizumab, a recombinant humanized, antihuman monoclonal antibody, can be effective in improving visual acuity and reducing vitreous haze in patients with noninfectious uveitis, according to a recent study.
JIA-associated uveitis is a challenging inflammatory condition in the pediatric population. Adalimumab was found to be effective and safe in reducing ocular imflammation within 2 months and well tolerated over 12 months in JIA-associated uveitis.
Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
Recently, evidence has been accumulating to support the theory that cerebrospinal fluid pressure (CSFp) is also important in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG), and the relationship has potential implications for clinical practice, said R. Rand Allingham, MD.
Cataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone. Surgeons must answer a different set of questions and consider alternative management strategies, said Debra A. Goldstein, MD, FRSC, professor of ophthalmology and director of the Uveitis Service, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago.
Immunotherapy and other investigational treatments appear to be promising for uveal melanoma, according to Carol Shields, MD. “There have been interesting new avenues for therapy,” said Dr. Shields, co-director, Ocular Oncology Service, Wills Eye Hospital, Philadelphia.